IMPORTANT SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit Has Been Filed Against Sientra, Inc. in the United States District Court for the Central District of California -- SIEN

Lead Plaintiff Deadline is November 24, 2015


NEW YORK, Oct. 02, 2015 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of Sientra, Inc. (Nasdaq:SIEN) (“Sientra” or the “Company”) securities during the period between March 18, 2015 and September 24, 2015, inclusive (the “Class Period”). Shareholders of Sientra with significant  losses are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.

If you purchased the shares of Sientra during the period from March 18, 2015 and September 24, 2015, inclusive, you may, no later than November 24, 2015, request that the Court appoint you lead plaintiff of the proposed class.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material  adverse facts about the Company’s  business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements, and failed to  disclose material adverse facts about the Company’s business, operations, prospects and performance.  Specifically,  during the  Class Period,  defendants made  false and/or misleading statements  and/or failed  to disclose  that: (i)  Sientra’s exclusive reliance  on Silimed’s  Brazilian manufacturing  facilities  carried significant quality control  risks; (ii)  the manufacturing  processes at  the Silimed Rio de Janeiro manufacturing plant were contaminated; and (iii)  as  a result of the above,  the Company’s statements  regarding quality control  and other financial  statements  were  materially  false  and  misleading  at  all relevant times. 

On September 24, 2015,  it was announced that  the United Kingdom’s  Medicines and Healthcare  Products Regulatory  Agency (“MHRA”)  had suspended  sales  of Silimed products after an audit of Silimed’s manufacturing processes  revealed contamination in Silimed’s Rio de Janeiro manufacturing plant.  On this news, shares of Sientra  fell $10.88,  or nearly 53%,  to close  at $9.70 on September 24, 2015.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.  All e-mail correspondence should make reference to the “Sientra Investigation.”

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.


            

Contact Data